<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/">
<channel>
<title>Head &amp; Neck Cancer – DOI-Enriched Feed</title>
<link>https://colmmemedsurv.github.io/sentinelnode/</link>
<description>Curated head &amp; neck cancer literature with DOI, Crossref and PubMed enrichment.</description>
<lastBuildDate>Mon, 22 Dec 2025 01:30:57 +0000</lastBuildDate>
<item>
<title>[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials</title>
<link>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00616-3/fulltext?rss=yes</link>
<guid isPermaLink='true'>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00616-3/fulltext?rss=yes</guid>
<dc:creator>Jessica T Lovett, Michael T Wotman, Marshall Posner</dc:creator>
<prism:publicationName>The Lancet Oncology</prism:publicationName>
<prism:doi>10.1016/S1470-2045(25)00616-3</prism:doi>
<description>Journal: The Lancet Oncology | DOI: 10.1016/S1470-2045(25)00616-3</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: The Lancet Oncology</p>
<p><strong>Authors</strong>: Jessica T Lovett, Michael T Wotman, Marshall Posner</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/S1470-2045(25)00616-3'>10.1016/S1470-2045(25)00616-3</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>We read with interest the Article by Daniel Ma and colleagues in The Lancet Oncology.1 Ma and colleagues should be congratulated on completing a randomised trial of de-escalated radiotherapy in patients with p16-positive oropharyngeal squamous cell carcinoma. The authors report progression-free survival, local regional control, freedom from distant metastases, and overall survival as secondary endpoints. The de-escalation protocol resulted in a reduction in progression-free survival, local regional control, and systemic control in patients who received de-escalated treatment with extracapsular extension compared with patients who received standard of care.</p>
]]></content:encoded>
</item>
<item>
<title>[Correspondence] Misclassification of p16-positive, HPV-negative patients biases de-escalation trials – Authors&apos; reply</title>
<link>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00655-2/fulltext?rss=yes</link>
<guid isPermaLink='true'>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00655-2/fulltext?rss=yes</guid>
<dc:creator>David M Routman, James S Lewis, Daniel J Ma</dc:creator>
<prism:publicationName>The Lancet Oncology</prism:publicationName>
<prism:doi>10.1016/S1470-2045(25)00655-2</prism:doi>
<description>Journal: The Lancet Oncology | DOI: 10.1016/S1470-2045(25)00655-2</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: The Lancet Oncology</p>
<p><strong>Authors</strong>: David M Routman, James S Lewis, Daniel J Ma</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/S1470-2045(25)00655-2'>10.1016/S1470-2045(25)00655-2</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>We appreciate the important points raised by Jessica T Lovett and colleagues regarding p16 immunohistochemistry as a surrogate for HPV status in oropharyngeal squamous cell carcinoma in de-escalation studies such as MC1675.1 As they noted, the prognostic implications of p16 and HPV discordance have been previously analysed, such as in a multinational study by Mehanna and colleagues.2 Patients who were p16-positive and HPV-negative had an increased rate of cancer recurrence (hazard ratio 1·92, 95% CI 1·42–2·60).</p>
]]></content:encoded>
</item>
<item>
<title>Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006542?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006542?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107825</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107825</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107825'>10.1016/j.oraloncology.2025.107825</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>To develop a retropharyngeal lymph node (RLN)-based scoring system using anatomical features and to evaluate its utility in optimizing N classification in patients with nasopharyngeal carcinoma (NPC).</p>
]]></content:encoded>
</item>
<item>
<title>Jaw-in-a-day (JIAD) for malignant indications: A systematic review</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006529?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006529?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107823</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107823</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107823'>10.1016/j.oraloncology.2025.107823</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>None</p>
]]></content:encoded>
</item>
<item>
<title>Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006487?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006487?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107819</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107819</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107819'>10.1016/j.oraloncology.2025.107819</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>A report on the feasibility of sequential robotic-assisted neck dissection and robotic micro-surgical free flap reconstruction via a trans-hairline approach in oral cavity cancer patients.</p>
]]></content:encoded>
</item>
<item>
<title>Letter to the editor: Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525005342?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525005342?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107705</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107705</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107705'>10.1016/j.oraloncology.2025.107705</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>None</p>
]]></content:encoded>
</item>
<item>
<title>Methodological considerations in profiling the immune microenvironment and HPV status of oral multiple primary cancers</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006517?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006517?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107822</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107822</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107822'>10.1016/j.oraloncology.2025.107822</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>None</p>
]]></content:encoded>
</item>
<item>
<title>Refining surveillance in surgically treated HPV(+)OPSCC: The path to Risk-Adapted strategies</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006414?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006414?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107812</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107812</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107812'>10.1016/j.oraloncology.2025.107812</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>None</p>
]]></content:encoded>
</item>
<item>
<title>The diagnostic trade-off in post-treatment surveillance for HPV-positive oropharyngeal carcinoma</title>
<link>https://www.sciencedirect.com/science/article/pii/S136883752500627X?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S136883752500627X?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107798</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107798</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107798'>10.1016/j.oraloncology.2025.107798</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>None</p>
]]></content:encoded>
</item>
<item>
<title>Intrathyroid thymic carcinoma diagnosed following an odontogenic infection: Insights from a rare clinical presentation</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006268?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006268?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107797</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107797</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107797'>10.1016/j.oraloncology.2025.107797</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>None</p>
]]></content:encoded>
</item>
<item>
<title>Influencing factors on occurrence and prognosis of oral squamous cell carcinoma after organ transplantation</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006530?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006530?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107824</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107824</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107824'>10.1016/j.oraloncology.2025.107824</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Patients who undergo solid organ or hematopoietic stem cell transplantation are at an increased risk of developing oral squamous cell carcinoma (OSCC) due to prolonged immunosuppression. The specific characteristics and prognostic outcomes of OSCC in these post-transplant patients are not well understood. This study aims to investigate the risk, characteristics, and prognostic outcomes of OSCC in post-transplant patients.</p>
]]></content:encoded>
</item>
<item>
<title>Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006475?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006475?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107818</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107818</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107818'>10.1016/j.oraloncology.2025.107818</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>The major risk factor for vermilion lip squamous cell carcinoma (vlSCC) is excessive sunlight exposure. Population-based studies on treatment and outcome are lacking.</p>
]]></content:encoded>
</item>
<item>
<title>Is 55 years an optimal age cutoff point for clinical staging in T1 papillary thyroid cancer?</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006463?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006463?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107817</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107817</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107817'>10.1016/j.oraloncology.2025.107817</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>This study aims to determine the optimal age cutoff for T1 papillary thyroid cancer (PTC), with a particular focus on the T1a and T1b subgroups.</p>
]]></content:encoded>
</item>
<item>
<title>A pilot study of a digital workflow for navigated tumor bed marking to reduce clinical target volume during adjuvant radiotherapy for oral squamous cell carcinoma</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006499?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006499?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107820</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107820</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107820'>10.1016/j.oraloncology.2025.107820</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>The treatment of advanced-stage oral squamous cell carcinoma (OSCC) often requires adjuvant radiotherapy to improve the survival rate. Accurately defining the clinical target volume (CTV) is critical for radiation treatment to maximize the radiation dose and minimize negative side effects. However, precise planning remains difficult because of postoperative anatomical changes, which may lead to oversized volumes with increased collateral damage to adjacent tissues. The aim of this study is to suggest a digital planning algorithm to improve the precision of CTV definition.</p>
]]></content:encoded>
</item>
<item>
<title>Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006438?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006438?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107814</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107814</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107814'>10.1016/j.oraloncology.2025.107814</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Head and neck squamous cell carcinoma (HNSCC) remains a therapeutic challenge owing to its marked heterogeneity and limited immunotherapy efficacy, underscoring the need for improved therapeutic strategies and preclinical systems supporting clinical translation.</p>
]]></content:encoded>
</item>
<item>
<title>&lt;em&gt;NOTCH1&lt;/em&gt; loss promotes chemo and radio-resistance in head and neck cancer</title>
<link>https://www.sciencedirect.com/science/article/pii/S136883752500644X?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S136883752500644X?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107815</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107815</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107815'>10.1016/j.oraloncology.2025.107815</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with over 700,000 new cases diagnosed annually. HPV-associated HNSCC patients generally respond well to standard therapies; however, about 15-20 % experience recurrence, while the rate is approximately 50 % in non-HPV-associated HNSCC. Identifying biomarkers for treatment failure is crucial for optimizing treatment strategies. Our lab's whole genome sequencing (WGS) data has identified NOTCH1 mutations as enriched in recurrent HPV-positive HNSCC cases. This study investigates whether NOTCH1 deletion confers treatment resistance in both HPV-positive and HPV-negative HNSCC models.</p>
]]></content:encoded>
</item>
<item>
<title>Integrated geriatric assessment and intervention in the head and neck oncology care pathway reduces adverse events and does not affect survival</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006402?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006402?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107811</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107811</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107811'>10.1016/j.oraloncology.2025.107811</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>The number of older/frail patients with head and neck cancer (HNC) is increasing. They are more frail compared to patients with other malignancies. Therefore, geriatric care is increasingly integrated into the HNC care pathway. The aim of this study was to investigate how integrated geriatric care affects treatment outcomes in HNC patients irrespective of treatment intention.</p>
]]></content:encoded>
</item>
<item>
<title>Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006384?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006384?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107809</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107809</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107809'>10.1016/j.oraloncology.2025.107809</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>This study aimed to evaluate the antitumor effect and safety of neoadjuvant chemotherapy plus tislelizumab (a programmed death-1 inhibitor) for the treatment of resectable locally advanced oral or oropharyngeal squamous cell carcinoma (LAOOPSCC).</p>
]]></content:encoded>
</item>
<item>
<title>Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006426?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006426?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107813</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107813</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107813'>10.1016/j.oraloncology.2025.107813</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>To compare the quality of online information about human papillomavirus (HPV)-associated oropharyngeal cancer generated by a large language model with content retrieved from conventional web search and authoritative guideline-based sources.</p>
]]></content:encoded>
</item>
<item>
<title>Incidence of HPV-independent second primary malignancies following treatment of HPV-associated malignancy</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006190?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006190?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107790</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107790</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107790'>10.1016/j.oraloncology.2025.107790</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Second primary tumors after HPV-associated oropharyngeal squamous cell carcinoma (HPV + OPSCCa) are generally assumed to share the same HPV status as the index lesion, and current pathology guidelines discourage repeat HPV testing in recurrent disease. We retrospectively reviewed records from a tertiary academic center (2010-2024) to identify patients with a history of HPV + OPSCCa who subsequently developed an HPV-independent second primary head and neck squamous cell carcinoma. HPV status was determined by p16 immunohistochemistry, high-risk HPV DNA PCR, or RNA in situ hybridization. Eleven patients developed metachronous HPV-independent malignancies, representing an incidence of 2.5 %. The median interval between tumors was 8.8 years (range, 3.2-16.0 years). Second primaries most often arose in the contralateral base of tongue (55 %) or oral cavity (27 %). All patients had received definitive or adjuvant radiation for the initial tumor, and 73 % received concurrent chemotherapy. Four patients (36 %) reported a smoking history >10 pack-years. Most tumors at both time points were T1 or T2, but node-positive disease was more frequent in first primaries (82 % vs 18 %). Two patients developed a third HPV-independent primary tumor. These findings demonstrate that biologically discordant second primary head and neck cancers can emerge years after HPV + OPSCCa, challenging the assumption of HPV concordance and underscoring the need for long-term surveillance and reconsideration of repeat HPV testing in this population.</p>
]]></content:encoded>
</item>
<item>
<title>Establishment and characterization of a new immortalized human oral keratinocyte (HOK) cell line harboring various &lt;em&gt;TP53&lt;/em&gt; mutations</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006281?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006281?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107799</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107799</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107799'>10.1016/j.oraloncology.2025.107799</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Head and neck squamous cell carcinoma (HNSCC) is characterized by frequentTP53mutations, which include gain-of-function (GOF) variants that drive tumor progression and chemoresistance. While genomic evidence across multiple specimens ranging from oral pre-malignant lesions (OPL) through invasive and metastatic HNSCC indicates that TP53 loss or mutation occurs relatively early in HNSCC carcinogenesis, it has been difficult to discern how mutation of this tumor suppressor drives further tumor cell evolution and influences the tumor microenvironment to drive tumor progression. To address this question, we generated an immortalized human oral keratinocyte (iHOK) cell line expressing wt TP53 as well as TP53 mutant forms to determine how mutations impact functional and genomic characteristics of HOKs that can in turn drive their evolution to neoplastic cells. We established a novel panel of iHOK cell lines harboring distinctTP53mutations, including the high-risk C238F variant. Key results revealed significant phenotypic and molecular divergence: high-risk lines exhibited enhanced invasiveness and chemoresistance compared to low-risk counterparts. Weighted gene co-expression network analysis (WGCNA) linked high-risk mutations to pro-metastatic pathways and stress-response signatures, with the C238F line uniquely enriched for p53-related GOF mechanisms. Conversely, low-risk lines remained chemosensitive. These findings underscore the clinical relevance of mutation-specific iHOK models in determining the transcriptomic events that drive invasiveness and drug resistance and identify ways to intercept these phenotypes. By mirroring theTP53diversity observed in patient tumors, this cell line panel bridges a critical gap in head and neck carcinogenesis research, enabling mechanistic dissection of GOF phenotypes and preclinical evaluation of therapies in an array of TP53mutant cell models. Its significance lies in providing a validated, annotated resource that accelerates drug discovery and clarifies the role ofTP53mutational subtypes in HNSCC development and progression, offering a framework for future translational studies in genetically complex malignancies.</p>
]]></content:encoded>
</item>
<item>
<title>Hpv-driven rewiring of the tumor immune microenvironment through single-cell profiling informs prognosis and therapy in HNSCC</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006189?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006189?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107789</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107789</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107789'>10.1016/j.oraloncology.2025.107789</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Human papillomavirus (HPV) status is a key prognostic factor in head and neck squamous cell carcinoma (HNSCC), yet the precise immunological mechanisms and robust biomarkers for guiding personalized therapy remain elusive. This study aims to comprehensively delineate how HPV infection reprograms the tumor immune microenvironment (TIME) and to develop a novel prognostic model for stratifying patient outcomes and therapeutic responses.</p>
]]></content:encoded>
</item>
<item>
<title>Patterns of metastasis and nodal disease in tongue and buccal carcinomas: Case-based reflections in Delhi NCR Region</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006451?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006451?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107816</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107816</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107816'>10.1016/j.oraloncology.2025.107816</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Oral squamous cell carcinoma (OSCC) is a large source of cancer-related morbidity in India especially when it involves the tongue and the buccal mucosa. Despite the fact that TNM staging provides a global framework, regional patterns of metastasis, comorbidity interaction and concordance between imaging and pathology are not uniformly represented. This study will investigate nodal disease patterns in a group of people in the Delhi National Capital Region (NCR) and will suggest more specific treatments. The research aims to facilitate early diagnosis and intervention pathways and to reduce inequality in healthcare service provision.</p>
]]></content:encoded>
</item>
<item>
<title>Cerebrovascular events after head and neck radiation therapy: A systematic review and Meta-Analysis</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006396?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006396?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107810</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107810</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107810'>10.1016/j.oraloncology.2025.107810</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Several studies have demonstrated increased risk of cerebrovascular events, including carotid stenosis, stroke & transient ischemic attack, following head and neck radiation therapy (RT) for head and neck cancer (HNC). This systematic review reports the incidence of cerebrovascular events (CVEs) and the relative rate (RR) of ischemic stroke in patients treated with RT compared to non-RT populations.</p>
]]></content:encoded>
</item>
<item>
<title>Survival rates and oncologic outcomes of adeno squamous carcinoma of oral cavity: A systematic review</title>
<link>https://www.sciencedirect.com/science/article/pii/S1368837525006505?dgcid=rss_sd_all</link>
<guid isPermaLink='true'>https://www.sciencedirect.com/science/article/pii/S1368837525006505?dgcid=rss_sd_all</guid>
<prism:publicationName>ScienceDirect Publication: Oral Oncology</prism:publicationName>
<prism:doi>10.1016/j.oraloncology.2025.107821</prism:doi>
<description>Journal: ScienceDirect Publication: Oral Oncology | DOI: 10.1016/j.oraloncology.2025.107821</description>
<content:encoded><![CDATA[
<p><strong>Journal</strong>: ScienceDirect Publication: Oral Oncology</p>
<p><strong>DOI</strong>: <a href='https://doi.org/10.1016/j.oraloncology.2025.107821'>10.1016/j.oraloncology.2025.107821</a></p>
<hr/>
<p><strong>Abstract</strong></p>
<p>Adenosquamous carcinoma (ASC) of the oral cavity is an uncommon and aggressive malignancy characterized by squamous and glandular histologic components. Due to its rarity, clinical behavior and oncologic outcomes remain poorly defined.</p>
]]></content:encoded>
</item>
</channel></rss>